Back to Browse Journals » Journal of Asthma and Allergy » Volume 4

Clinical update on the use of biomarkers of airway inflammation in the management of asthma

Authors Wadsworth SJ, Sin DD, Dorscheid DR

Published Date June 2011 Volume 2011:4 Pages 77—86

DOI http://dx.doi.org/10.2147/JAA.S15081

Published 30 June 2011

SJ Wadsworth1,2, DD Sin1,2, DR Dorscheid1,2
1UBC James Hogg Research Centre, Providence Heart and Lung Institute, St Paul's Hospital, Vancouver, Canada; 2Department of Medicine, University of British Columbia, British Columbia, Canada

Abstract: Biological markers are already used in the diagnosis and treatment of cardiovascular disease and cancer. Biomarkers have great potential use in the clinic as a noninvasive means to make more accurate diagnoses, monitor disease progression, and create personalized treatment regimes. Asthma is a heterogeneous disease with several different phenotypes, generally triggered by multiple gene-environment interactions. Pulmonary function tests are most often used objectively to confirm the diagnosis. However, airflow obstruction can be variable and thus missed using spirometry. Furthermore, lung function measurements may not reflect the precise underlying pathological processes responsible for different phenotypes. Inhaled corticosteroids and ß2-agonists have been the mainstay of asthma therapy for over 30 years, but the heterogeneity of the disease means not all asthmatics respond to the same treatment. High costs and undesired side effects of drugs also drive the need for better targeted treatment of asthma. Biomarkers have the potential to indicate an individual's disease phenotype and thereby guide clinicians in their decisions regarding treatment. This review focuses on biomarkers of airway inflammation which may help us to identify, monitor, and guide treatment of asthmatics. We discuss biomarkers obtained from multiple physiological sources, including sputum, exhaled gases, exhaled breath condensate, serum, and urine. We discuss the inherent limitations and benefits of using biomarkers in a heterogeneous disease such as asthma. We also discuss how we may modify our study designs to improve the identification and potential use of potential biomarkers in asthma.

Keywords: asthma, inflammation, airway biomarkers, urinary biomarkers, serum biomarkers

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration

Keane PA, de Salvo G, Sim DA, Goverdhan S, Agrawal R, Tufail A

Clinical Ophthalmology 2015, 9:353-366

Published Date: 17 February 2015

Cost-effectiveness analysis on the use of rFSH + rLH for the treatment of anovulation in hypogonadotropic hypogonadal women

Papaleo E, Alviggi C, Colombo GL, Pisanelli C, Ripellino C, Longobardi S, Canonico PL

Therapeutics and Clinical Risk Management 2014, 10:479-484

Published Date: 25 June 2014

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis

Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:183-199

Published Date: 19 March 2012

Pegylated liposomal doxorubicin in ovarian cancer

Robert Strother, Daniela Matei

Therapeutics and Clinical Risk Management 2009, 5:639-650

Published Date: 10 August 2009

Cognitive impairment after cerebrovascular stroke: Relationship to vascular risk factors

Eman M Khedr, Sherifa A Hamed, Hala K El-Shereef, Ola A Shawky, Khalid A Mohamed, et al

Neuropsychiatric Disease and Treatment 2009, 5:103-116

Published Date: 15 February 2009